Prostate Cancer Trial, Recruiting NCT05597852 Sponsor: Sunnybrook Health Sciences Centre Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT05597852
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with locally returning prostate cancer, confirmed by both tissue biopsy and imaging scans
  • People who are willing to give their agreement to take part in this clinical trial
  • People who are able and willing to fill out two health-related questionnaires (called EPIC and EQ-5D)

Who may not be able to join:

  • People for whom an MRI scan of the prostate is not safe or suitable
  • People taking blood-thinning medications that cannot be safely stopped
  • People who have been diagnosed with a condition that causes abnormal bleeding
  • People with poor urinary function before treatment, measured by a symptom score above 20 on a standard prostate urinary questionnaire (called the IPSS)
  • People whose cancer appears to no longer be responding to hormone treatment, based on specific PSA and testosterone blood test levels — or people who were put on a particular type of hormone therapy because their PSA levels were rising (confirm with trial site)
  • People whose staging scans show cancer has spread to lymph nodes outside the pelvis or to other parts of the body
  • People who have previously received a specific type of high-dose, short-course radiotherapy (where each treatment dose was 5Gy or higher)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amandeep Taggar, MD, Sunnybrook

Phone: 416 480 6165

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 November 2021
Est. completion
30 November 2022

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Feasibility of SpaceOAR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov